Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.45 |
| ▸ | ARG1 | P05089 | 1/20 | 0.43 |
| ▸ | ARG2 | P78540 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 4/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1819135 | 1.00 | HRH3 (0.56) | HRH3SLC6A2SLC6A4SLC6A3ARG1 | |
| SCHEMBL440476 | 0.87 | SLC6A2 (0.56) | HRH3SLC6A2SLC6A4SLC6A3ARG1 | |
| SCHEMBL414249 | 0.87 | SLC6A2 (0.56) | HRH3SLC6A2SLC6A4SLC6A3ARG1 | |
| SCHEMBL10956783 | 0.87 | SLC6A2 (0.56) | HRH3SLC6A2SLC6A4SLC6A3ARG1 | |
| SCHEMBL1816048 | 0.86 | SLC6A2 (0.44) | HRH3SLC6A2SLC6A4SLC6A3ARG1 | |
| SCHEMBL1817184 | 0.86 | SLC6A2 (0.44) | HRH3SLC6A2SLC6A4SLC6A3ARG1 | |
| SCHEMBL4849081 | 0.86 | SLC6A2 (0.44) | HRH3SLC6A2SLC6A4SLC6A3ARG1 | |
| SCHEMBL29352273 | 0.86 | SLC6A2 (0.44) | HRH3SLC6A2SLC6A4SLC6A3ARG1 | |
| SCHEMBL11242292 | 0.86 | SLC6A2 (0.44) | HRH3SLC6A2SLC6A4SLC6A3ARG1 | |
| SCHEMBL1818182 | 0.86 | SLC6A2 (0.44) | HRH3SLC6A2SLC6A4SLC6A3ARG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122055379-A | Compounds containing one or more diboronate esters and related insulin analogues | 普罗托莫科技公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-119677541-A | Aromatic boron-containing compounds and related insulin analogues | 原聚体科技公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-113967258-B | FAP-activated therapeutic agents and related uses | 塔夫茨大学信托人 | 2024-07-02 | — | — | CN | disclosed |
| CN-116917297-A | Aromatic boron-containing compounds and insulin analogues | 原聚体科技公司 | 2023-10-20 | — | — | CN | disclosed |
| US-20230134116-A1 | CONJUGATES FOR SELECTIVE RESPONSIVENESS TO VICINAL DIOLS | PROTOMER TECHNOLOGIES, INC. | 2023-05-04 | — | — | US | disclosed |
| CN-115843257-A | Conjugates for selective responsiveness to vicinal diols | 原聚体科技公司 | 2023-03-24 | — | — | CN | disclosed |
| EP-4126058-A1 | CONJUGATES FOR SELECTIVE RESPONSIVENESS TO VICINAL DIOLS | Protomer Technologies Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| WO-2021202802-A1 | CONJUGATES FOR SELECTIVE RESPONSIVENESS TO VICINAL DIOLS | PROTOMER TECHNOLOGIES INC. (US) | 2021-10-07 | — | — | WO | disclosed |
| WO-2021081110-A2 | PEPTIDES AND USE THEREOF | ANEXIGEN, INC. (US) | 2021-04-29 | — | — | WO | disclosed |
| US-4316905-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1982-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230134116-A1 | CONJUGATES FOR SELECTIVE RESPONSIVENESS TO VICINAL DIOLS | GPR119, GLP1R, IAPP | HRH3 1847/4885SLC6A2 548/4885SLC6A4 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.